VICC Signs on with Open Biosystems' Open Access™ Program for Breast Cancer Research
Complete the form below to unlock access to ALL audio articles.
Open Biosystems, Inc. has announced that Vanderbilt-Ingram Cancer Center has joined its Open Access Program for RNAi and cDNA resources.
The Open Access RNAi Program is designed to provide the Cancer Center with access to Open Biosystems' whole-genome lentiviral human and mouse shRNAmir libraries for RNAi as well as the Mammalian Gene Collection (MGC) complementary DNA (cDNA) collection.
Currently, Vanderbilt-Ingram is utilizing these tools to advance research efforts that may lead to chemotherapeutic treatment options with diminished side-effects for those suffering from breast cancer.
The Cancer Center is also expanding use of these tools to study diabetes, digestive disorders, inflammation and neuroscience.
Vanderbilt-Ingram places emphasis on translational research that connects laboratory discoveries to the clinic and hospital.
Open Biosystems' Open Access Program provides Vanderbilt-Ingram with advanced RNAi and cDNA technologies that can be shared across the University, spanning various areas of research.
Through the program, Open Biosystems also provides participants with continual library updates and upgrades, as well as partner specific technical support designed to ensure that researchers can take advantage of the resources the program offers.
"By empowering our investigators with the latest tools and technologies to unravel the complexities of the human genome, our goal is to better understand and better treat devastating diseases such as breast cancer," said Shawn Levy, PhD, Director of the RNAi Core Facility at Vanderbilt-Ingram.
"Through the RNAi program we will be able to focus further on mechanisms of cancer pathogenesis and potential biomarkers that can lead to the development of novel molecular therapeutics."
"The Open Access Program underscores our goal to provide the latest RNAi and cDNA tools and technologies available to assist universities in the understanding of gene function," said Troy Moore, chief technical officer and co-founder of Open Biosystems.
"This important research will ultimately lead to improved disease diagnosis and patient care."
"By taking part in the Open Access Program, Vanderbilt University and the Vanderbilt-Ingram Cancer Center have affordable access to the latest RNAi and cDNA tools to accelerate scientific breakthroughs."
